GIP Benefits: What Studies Report

Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone released after nutrient intake. A 2023 review of incretin hormones in type 2 diabetes described GIP and GLP-1 as the two hormones responsible for the incretin effect, the amplification of insulin secretion that follows oral compared with intravenous glucose (PMID 37430117). A 2025 review of incretin hormones and obesity described these same hormones as regulators of energy balance and appetite as well as of glucose handling (PMID 39576749).

This page organises what published studies have actually measured and reported, by outcome domain. It is descriptive, not prescriptive. A broader background primer sits at /learn/gip/.

How "GIP benefits" appear in the published literature

An important framing point comes first. The human outcome literature summarised here almost never tested GIP administered alone. It tested molecules that engage the GIP receptor alongside the GLP-1 receptor, or alongside GLP-1 and glucagon receptors. A 2024 review of mechanisms and therapeutic applications described GLP-1 and dual GIP/GLP-1 receptor agonists together as a therapeutic class with overlapping metabolic mechanisms (PMID 39114288). A 2025 review of the obesity drug pipeline placed multi-receptor incretin agents, including GIP-containing combinations, among the agents under development and evaluation (PMID 38302593).

So when a result below is described as reported for a dual or triple agonist, the GIP component cannot be separated from the GLP-1 or glucagon components in that trial. Researchers reported combined-molecule outcomes, not isolated GIP outcomes.

Outcome domains at a glance

Glucose control and insulin secretion

The oldest and least contested domain is glycaemic. The 2023 Diabetologia review of incretin hormones and type 2 diabetes described the physiology of GIP and GLP-1 and their relationship to insulin secretion and to the development of incretin-based therapies (PMID 37430117). The 2024 mechanisms review described dual GIP/GLP-1 receptor agonism as a strategy applied to glycaemic and metabolic management, and summarised the proposed mechanisms behind those applications (PMID 39114288).

Two cautions belong in the same breath. First, these are reviews, not head-to-head trials of GIP by itself. Second, the insulinotropic action attributed to GIP in that physiology literature is described as glucose-dependent, which is a mechanistic description rather than an outcome measured in a clinical endpoint trial (PMID 37430117).

Body weight and appetite

A 2025 Bayesian network meta-analysis compared GLP-1 receptor agonists, dual agonists and retatrutide for weight loss in adults with overweight or obesity, and reported comparative efficacy and safety estimates across those agent classes (PMID 40685589). In that analysis, the multi-receptor agents, which include the GIP/GLP-1 dual agonist, were reported as producing greater weight reduction than single-receptor GLP-1 comparators (PMID 40685589).

A 2025 expert review of tirzepatide for overweight and obesity management summarised the clinical development programme for that dual GIP/GLP-1 receptor agonist in weight management, including its efficacy and tolerability profile (PMID 39632534). A 2025 review of retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, described its position in obesity pharmacotherapy and the trial evidence reported to date (PMID 40563436).

On the mechanism of appetite effects, the 2025 Journal of Physiology review of incretin hormones and obesity described how incretin signalling relates to appetite regulation and body weight, and noted that the role of GIP in energy balance remains an area of active investigation rather than a settled question (PMID 39576749).

Why the GIP contribution is hard to isolate

No trial cited here randomised participants to GIP receptor agonism alone versus GLP-1 receptor agonism alone within the same molecule. The network meta-analysis compared whole agents, not receptor components (PMID 40685589). Readers who want to attribute a specific share of weight change to GIP will not find that attribution in the papers summarised here.

Liver outcomes (MASLD and MASH)

A 2024 review in World Journal of Gastroenterology examined GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists as therapeutic agents for metabolic dysfunction-associated steatohepatitis, describing the rationale and the evidence base for each receptor combination (PMID 39735270). The review framing is important: it discussed these molecules as investigational or emerging options in steatohepatitis rather than describing a single established liver outcome for GIP (PMID 39735270).

Cardiovascular outcomes

This is a domain where the distinction between a planned trial and a reported result matters. The SURPASS-CVOT publication cited here described the design and baseline characteristics of a trial comparing tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease (PMID 37758044). A design paper reports who was enrolled and how outcomes will be measured; it does not report the event outcome (PMID 37758044).

At review level, a 2026 Lancet review examined GLP-1 receptor agonists and next-generation incretin-based medications across metabolic, cardiovascular and renal endpoints (PMID 41547366). A 2025 review in Medicina Clínica examined the impact of GLP-1-based therapies on obesity-related comorbidities and diseases (PMID 41016281). Both are syntheses rather than new trials, and neither isolates GIP receptor agonism as an independent variable (PMID 41547366).

Renal and comorbidity outcomes

The 2026 Lancet review grouped renal endpoints alongside cardiovascular and metabolic endpoints when describing incretin-based medications, including next-generation multi-receptor agents (PMID 41547366). The 2025 comorbidity review described how obesity-related conditions have been assessed as secondary targets of incretin-based treatment rather than as primary GIP-specific endpoints (PMID 41016281).

Receptor pharmacology: what laboratory work reported

A 2020 JCI Insight study characterised tirzepatide in laboratory receptor systems and reported that it behaved as an imbalanced and biased dual GIP and GLP-1 receptor agonist, with activity weighted differently between the two receptors (PMID 32730231). That work was in-vitro and preclinical pharmacology, not a clinical outcome study, and researchers described signalling behaviour rather than patient benefit (PMID 32730231). It is frequently cited in discussions of why a GIP-containing molecule may behave differently from a pure GLP-1 agent (PMID 39114288).

Claims with little or no support in the papers summarised here

Several outcomes people associate with "GIP benefits" were not endpoints in any paper cited on this page. On each, the honest answer is that the evidence set here is silent:

• GIP given alone as a standalone injectable for weight loss. The weight-loss evidence summarised here concerns GLP-1 agents, dual agonists and retatrutide, not monotherapy GIP (PMID 40685589).
• Muscle growth, athletic performance or recovery. No cited paper reported these outcomes; the reviews addressed metabolic, cardiovascular and renal endpoints (PMID 41547366).
• Cognition, longevity or anti-ageing endpoints. These were outside the scope of the reviews cited here, which addressed obesity and its comorbidities (PMID 41016281).
• A settled answer on GIP receptor agonism versus antagonism. The 2025 incretin-and-obesity review described GIP's contribution to energy balance as an area still being worked out (PMID 39576749).

Adverse Events: What Studies Report

Safety in this literature is reported for the whole molecule, not for the GIP component. The 2025 Bayesian network meta-analysis assessed safety alongside efficacy for GLP-1 receptor agonists, dual agonists and retatrutide in adults with overweight or obesity (PMID 40685589). The 2025 expert review of tirzepatide summarised the tolerability profile observed in its clinical programme, with gastrointestinal effects described as the most common category of adverse event in incretin-based treatment (PMID 39632534). The 2025 retatrutide review similarly discussed safety alongside efficacy for the triple receptor agonist (PMID 40563436). The SURPASS-CVOT design paper described a population with type 2 diabetes and established atherosclerotic cardiovascular disease, a group in which safety monitoring was built into the trial structure (PMID 37758044).

Reading this evidence carefully

1. Check the study type. A design-and-baseline paper reports who was enrolled, not what happened (PMID 37758044).
2. Check whether the finding is human. Receptor-signalling characterisation is laboratory pharmacology (PMID 32730231).
3. Check what was actually compared. Meta-analyses in this area compared agents, not receptor components (PMID 40685589).
4. Check the population. Results reported in adults with type 2 diabetes or obesity do not automatically describe other groups (PMID 39632534).

Separately from the science, research-chemical or "research use only" material is not an approved medicine, and approved incretin-based products are prescription medicines evaluated through the trial programmes described in these reviews (PMID 38302593).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision.

References

• Incretin hormones and type 2 diabetes (Diabetologia, 2023)
• Incretin hormones and obesity (The Journal of Physiology, 2025)
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists (Frontiers in Endocrinology, 2024)
• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA (Obesity, 2025)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis (World Journal of Gastroenterology, 2024)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (Lancet, 2026)
• GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases (Medicina Clínica, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)